The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $668,569 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Schepens Eye Research Institute, Inc., a non-profit organization, to characterize and optimize a novel single-dose, thermostable, and durable vaccine platform called PARVAX. The research aims to investigate the mechanism behind the potency and durability of the PARVAX platform, enhance its potency through rational engineering approaches, and demonstrate its efficacy as a vaccine platform beyond COVID-19 by exploring its ability to induce serum and mucosal immunity and protection against influenza viruses. This project is highly relevant for pandemic preparedness, as it will enable the rapid design of new and preclinically derisked PARVAX candidates for existing and future pathogens, and has the potential to provide insights on improving the durability, breadth, and mucosal immunity of other vaccine platforms.
Generated 3/4/25, 7:42 AM